News
Corcept Therapeutics Incorporated (NASDAQ: CORT) is one of the growth stocks that could double by 2027. On July 14, CORT ...
14d
Zacks Investment Research on MSNCorcept Seeks FDA Approval for Relacorilant in Ovarian CancerCorcept Therapeutics CORT announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Low Risk High Growth Stocks to Buy. Analysts are ...
Corcept Submits NDA For Relacorilant To Treat Platinum-Resistant Ovarian Cancer July 14, 2025 — 01:03 pm EDT Written by RTTNews.com for RTTNews -> ...
Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer Provided by Business Wire Jul 14, 2025, 5:00:00 AM ...
By Colin Kellaher Corcept Therapeutics has filed for U.S. Food and Drug Administration approval of its relacorilant drug candidate for the treatment of patients with platinum-resistant ovarian cancer.
Corcept is studying relacorilant in a variety of serious disorders in addition to ovarian cancer, including endogenous hypercortisolism (Cushing’s syndrome) and prostate cancer.
By Colin Kellaher Corcept Therapeutics has filed for U.S. Food and Drug Administration approval of its relacorilant drug candidate for the treatment of patients with platinum-resistant ovarian cancer.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results